155 related articles for article (PubMed ID: 25979262)
41. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
42. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
44. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Perloff MD; Von Moltke LL; Greenblatt DJ
Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
[TBL] [Abstract][Full Text] [Related]
45. CRISPR/Cas9 Genetic Modification of
Dorr CR; Remmel RP; Muthusamy A; Fisher J; Moriarity BS; Yasuda K; Wu B; Guan W; Schuetz EG; Oetting WS; Jacobson PA; Israni AK
Drug Metab Dispos; 2017 Aug; 45(8):957-965. PubMed ID: 28533324
[TBL] [Abstract][Full Text] [Related]
46. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Hartwell PS; Raisys VA; Marsh CL; McVicar JP; Barr DM
J Pharmacol Exp Ther; 1994 Oct; 271(1):549-56. PubMed ID: 7965755
[TBL] [Abstract][Full Text] [Related]
47. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
49. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.
Paulussen A; Lavrijsen K; Bohets H; Hendrickx J; Verhasselt P; Luyten W; Konings F; Armstrong M
Pharmacogenetics; 2000 Jul; 10(5):415-24. PubMed ID: 10898111
[TBL] [Abstract][Full Text] [Related]
50. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
51. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
52. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
[TBL] [Abstract][Full Text] [Related]
53. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
54. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele.
Sim SC; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Pharmacogenet Genomics; 2005 Sep; 15(9):625-31. PubMed ID: 16041241
[TBL] [Abstract][Full Text] [Related]
55. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
56. Developmental expression of the major human hepatic CYP3A enzymes.
Stevens JC; Hines RN; Gu C; Koukouritaki SB; Manro JR; Tandler PJ; Zaya MJ
J Pharmacol Exp Ther; 2003 Nov; 307(2):573-82. PubMed ID: 12975492
[TBL] [Abstract][Full Text] [Related]
57. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression.
Vyhlidal CA; Gaedigk R; Leeder JS
Drug Metab Dispos; 2006 Jan; 34(1):131-7. PubMed ID: 16243958
[TBL] [Abstract][Full Text] [Related]
58. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.
Bolbrinker J; Seeberg S; Schostak M; Kempkensteffen C; Baelde H; de Heer E; Kreutz R
Drug Metab Dispos; 2012 Apr; 40(4):639-41. PubMed ID: 22214815
[TBL] [Abstract][Full Text] [Related]
59. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
[TBL] [Abstract][Full Text] [Related]
60. A significant drug-metabolizing role for CYP3A5?
Williams JA; Cook J; Hurst SI
Drug Metab Dispos; 2003 Dec; 31(12):1526-30. PubMed ID: 14625349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]